Results 71 to 80 of about 10,317 (226)

Experience Using Efgartigimod to Treat Juvenile Myasthenia Gravis in China: A Multicenter Retrospective Study

Muscle &Nerve, Volume 73, Issue 6, Page 1025-1031, June 2026.
ABSTRACT Introduction/Aims Current therapeutic management of juvenile myasthenia gravis (JMG) predominantly relies on conventional immunosuppressive therapies and expert consensus extrapolated from adult data, creating a critical gap in high‐quality, pediatric‐specific clinical evidence.
Jing Lin, Guoyan Qi, Susan Luo, Qilong Jiang, Bitao Bu, Min Liu, Yuzhen Wei, Meigui Han, Junhong Yang, Zhilan Zhao, Lili Zhang, Yifan Zhang, Haoyou Xu, Xingjie Hao, Zhijun Li   +14 more
wiley   +1 more source

Myasthenia Gravis Patients with Anti-MuSK Antibodies [PDF]

, 2009
In myasthenia gravis (MG) patients without detectable anti-acetylcholine receptor (anti-AChR) antibody, referred to as seronegative myasthenia gravis patients, there is a variable proportion of patients with antibodies against the muscle-specific kinase (
Davorka Vranješ, Ervina Bilić, Marija Šoštarko, Marija Žagar, Milica Trbojević Čepe, Željka Vogrinc   +5 more
core   +1 more source

Ruolo delle heat shock proteins nella patogenesi della miastenia gravis [PDF]

, 2010
Myasthenia Gravis (MG) is an autoimmune disorder of the neuromuscolar junction mediated by specific antibodies to the nicotinic acetylcholine receptors. Several clinical and experimental studies have confirmed that the HSPs are involved in the process of
MARINO GAMMAZZA, Antonella, ZUMMO, Leila
core   +1 more source

Safety of Prednisone for Ocular Myasthenia Gravis [PDF]

Journal of Neuro-Ophthalmology, 2012
Treatment with chronic corticosteroids has been associated with frequent significant adverse effects. We hypothesized that a long-term low-dose prednisone regimen for ocular myasthenia gravis (OMG) would have a low rate of major side effects.Consecutive OMG patients from a single institution over a 16-year period and treated with ≥1 month of daily ...
Beau B, Bruce, Mark J, Kupersmith
openaire   +2 more sources

Increased Prevalence of Extrathymic Neoplasms in Myasthenia Gravis Patients‐A Population‐Based, Matched Case–Control Study

Muscle &Nerve, Volume 73, Issue 6, Page 1016-1024, June 2026.
ABSTRACT Introduction/Aims Myasthenia gravis (MG) is associated with thymic neoplasms. However, an increased prevalence of extrathymic neoplasms has also been reported. This study aimed to evaluate the rates of malignancy in MG patients while accounting for risk factors such as disease characteristics and immunomodulatory treatments.
Keshet Pardo, Tasneem Kab, Mark A. Hellmann, Itay Lotan, Tzippy Shochat, Nadav Loebl, Bar Yacobi, Yitzhak Friedman, Leor Perl, Nitai Shimon, Yiska Loewenberg Weisband, Liya Bieber, Eitan Auriel, Adi Wilf‐Yarkoni   +13 more
wiley   +1 more source

Familial Autoimmune Myasthenia Gravis (Report Of 3 Cases)

Annals of Indian Academy of Neurology, 2003
Familial Autoimmune myasthenia gravis is rare, occurring in only about 1.3% cases of myasthenia gravis (MG). Here in we report a family with three family members affected by MG. Proband presented with generalised myasthenia where as the other two
Girija A. S, Madhukar M, John John K
doaj  

Study on the clinical and electrophysiological characteristics of nerve function in myasthenia gravis patients in Vietnam

SAGE Open Medicine
Background: In Vietnam, there is limited research on the role of nerve conduction in myasthenia gravis and its association with clinical features. Objective: This study aims to describe the electrophysiological features in patients with myasthenia gravis.
Tho Kieu Anh Pham, Phuong Van Pham, Tung Dinh Le, Binh Thanh Nguyen, Trung Kien Nguyen, Tam Thai Thanh Tran, Sam Phan Hai Nguyen, Minh Van Le   +7 more
doaj   +1 more source

Myasthenia gravis patients with anti-MuSK antibodies [Miastenija gravis kod bolesnika s pozitivnim protutijelima na MuSK] [PDF]

, 2009
In myasthenia gravis (MG) patients without detectable anti-acetylcholine receptor (anti-AChR) antibody, referred to as seronegative myasthenia gravis patients, there is a variable proportion of patients with antibodies against the muscle specific kinase (
Bilić, Ervina, Trbojević Čepe, Milica, Vogrinc, Željka, Vranješ, Davorka, Šoštarko, Marija, Žagar, Marija   +5 more
core  

The Effect of Thymectomy on the Incidence of Extrathymic Cancers and Autoimmune Diseases in Patients With Non‐Thymomatous Myasthenia Gravis

Muscle &Nerve, Volume 73, Issue 6, Page 1065-1072, June 2026.
ABSTRACT Introduction/Aims Thymectomy is associated with positive effects on myasthenia gravis (MG), but there is conflicting evidence regarding potential deleterious long‐term outcomes, such as increased cancer and autoimmune disease risk. We aimed to assess these outcomes in thymectomized versus non‐thymectomized MG patients.
Mohamed Khateb, Adnan Almasri, Carolina Barnett‐Tapia, Vera Bril   +3 more
wiley   +1 more source

Long-term safety and efficacy of eculizumab in generalized myasthenia gravis [PDF]

, 2019
Introduction: Eculizumab is effective and well tolerated in patients with antiacetylcholine receptor antibody-positive refractory generalized myasthenia gravis (gMG; REGAIN; NCT01997229). We report an interim analysis of an open-label extension of REGAIN,
Andersen, Henning, Barohn, Richard J, Benatar, Michael, Burns, Ted M, Casasnovas, Carlos, De Bleecker, Jan, Fujita, Kenji P, Howard, James F, Jr., Illa, Isabel, Jacob, Saiju, Kissel, John T, Mantegazza, Renato, Muppidi, Srikanth, Murai, Hiroyuki, Nowak, Richard J, O'Brien, Fanny L, Utsugisawa, Kimiaki, Vissing, John, Vu, Tuan H, Wang, Jing Jing   +19 more
core   +2 more sources